By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login
Logo for company Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc. (LRMR)

NASDAQ Currency in USD
$4.17
+$0.17
+4.25%
Last Update: 11 Sept 2025, 20:00
$356.91M
Market Cap
-2.64
P/E Ratio (TTM)
Forward Dividend Yield
$1.61 - $9.50
52 Week Range

LRMR Stock Price Chart

Explore Larimar Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze LRMR price movements and trends.

LRMR Company Profile

Discover essential business fundamentals and corporate details for Larimar Therapeutics, Inc. (LRMR) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Biotechnology

IPO Date

19 Jun 2014

Employees

65.00

CEO

Carole S. Ben-Maimon

Description

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

LRMR Financial Timeline

Browse a chronological timeline of Larimar Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 28 Apr 2026

Upcoming earnings on 29 Oct 2025

EPS estimate is -$0.40.

Earnings released on 14 Aug 2025

EPS came in at -$0.41 surpassing the estimated -$0.47 by +12.77%.

Earnings released on 30 Apr 2025

EPS came in at -$0.46 falling short of the estimated -$0.42 by -9.52%.

Earnings released on 24 Mar 2025

EPS came in at -$0.45 falling short of the estimated -$0.29 by -55.17%, while revenue for the quarter reached $241.00K .

Earnings released on 30 Oct 2024

EPS came in at -$0.24 surpassing the estimated -$0.37 by +35.14%.

Earnings released on 7 Aug 2024

EPS came in at -$0.34 falling short of the estimated -$0.32 by -6.25%.

Earnings released on 9 May 2024

EPS came in at -$0.27 falling short of the estimated -$0.24 by -12.50%.

Earnings released on 14 Mar 2024

EPS came in at -$0.30 falling short of the estimated -$0.25 by -20.00%.

Earnings released on 14 Nov 2023

EPS came in at -$0.21 surpassing the estimated -$0.23 by +8.70%.

Earnings released on 10 Aug 2023

EPS came in at -$0.19 surpassing the estimated -$0.21 by +9.52%.

Earnings released on 15 May 2023

EPS came in at -$0.15 surpassing the estimated -$0.25 by +40.00%.

Earnings released on 14 Mar 2023

EPS came in at -$0.21 surpassing the estimated -$0.78 by +73.08%.

Earnings released on 10 Nov 2022

EPS came in at -$0.37 surpassing the estimated -$0.50 by +26.00%.

Earnings released on 11 Aug 2022

EPS came in at -$0.47 surpassing the estimated -$0.62 by +24.19%.

Earnings released on 12 May 2022

EPS came in at -$0.49 surpassing the estimated -$0.62 by +20.97%.

Earnings released on 25 Mar 2022

EPS came in at -$0.50 surpassing the estimated -$0.72 by +30.56%.

Earnings released on 12 Nov 2021

EPS came in at -$0.92 falling short of the estimated -$0.62 by -48.39%.

Earnings released on 12 Aug 2021

EPS came in at -$0.79 falling short of the estimated -$0.73 by -8.22%.

Earnings released on 10 May 2021

EPS came in at -$0.76 surpassing the estimated -$0.93 by +18.28%.

Earnings released on 4 Mar 2021

EPS came in at -$0.89 falling short of the estimated -$0.72 by -23.61%.

Earnings released on 10 Nov 2020

EPS came in at -$0.64 .

LRMR Stock Performance

Access detailed LRMR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More
Command Palette
Search for a command to run